Oncotelic Therapeutics Leverages AI and Robotics to Transform Pharmaceutical Manufacturing

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is making a strategic pivot beyond its clinical-stage roots, venturing into the rapidly evolving intersection of artificial intelligence and industrial automation. The company, traditionally focused on oncology and immunotherapy, has announced a partnership with TechForce Robotics to commercialize a next-generation, AI-enhanced platform designed for regulated pharmaceutical environments. This move signals a broader trend of biotech firms diversifying into automation to address efficiency and compliance challenges in drug manufacturing.

At the core of this initiative is Oncotelic’s proprietary PDAOAI platform, an AI-driven system that improves compliance, monitoring, and operational intelligence. By integrating this software with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings. The partnership positions Oncotelic to capitalize on the growing demand for automation in pharma, where regulatory compliance and precision are paramount.

The announcement, featured in a recent article (https://ibn.fm/WTlVQ), highlights the potential for AI to revolutionize pharmaceutical operations. By automating repetitive tasks and providing real-time data analytics, the PDAOAI platform could reduce human error, accelerate production timelines, and ensure consistent adherence to Good Manufacturing Practices (GMP). This is particularly critical for companies like Oncotelic, which are developing therapies for high-unmet-need cancers and rare pediatric indications.

Oncotelic’s expansion into automation does not diminish its core mission. The company remains a clinical-stage biopharmaceutical firm focused on oncology and immunotherapy, with a pipeline of late-stage therapeutic candidates. Its CEO, Dr. Vuong Trieu, has filed over 150 patent applications and holds 39 issued U.S. patents, underscoring the company’s innovative capacity. Beyond internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures, such as its 45% stake in GMP Bio, which advances complementary therapies in oncology and rare diseases.

The implications of this announcement extend beyond Oncotelic. As the pharmaceutical industry grapples with rising costs and complex supply chains, AI-driven automation offers a pathway to greater efficiency and reliability. For investors, Oncotelic’s pivot could open new revenue streams while de-risking its drug development pipeline. The company’s newsroom (https://nnw.fm/OTLC) provides updates on these developments.

By marrying AI with pharmaceutical manufacturing, Oncotelic is positioning itself at the forefront of a technological shift that could redefine how drugs are produced. While the partnership is still in its early stages, the potential for scalable, compliant automation makes this a development worth monitoring for both industry observers and investors.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Leverages AI and Robotics to Transform Pharmaceutical Manufacturing.

The post Oncotelic Therapeutics Leverages AI and Robotics to Transform Pharmaceutical Manufacturing appeared first on citybuzz.